MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-12-2022
ResMed Cost of Revenue 2011-2026 | RMD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue ResMed
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.55 B | 1.36 B | 1.24 B | 1.11 B | 1.01 B | 865 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.55 B | 865 M | 1.19 B |
Quarterly Cost of Revenue ResMed
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 373 M | 391 M | 398 M | 788 M | 322 M | 338 M | 313 M | 338 M | 313 M | 309 M | 289 M | 309 M | 276 M | 277 M | 245 M | 267 M | 245 M | 251 M | 218 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 788 M | 218 M | 329 M |
Cost of Revenue of other stocks in the Medical instruments industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
107 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
6.65 B | $ 19.93 | 0.99 % | $ 10.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
8.41 M | $ 8.71 | 3.75 % | $ 176 M | USA |
 |
Alcon
ALC
|
3.58 B | $ 81.19 | 0.07 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
118 M | $ 36.37 | -1.57 % | $ 1.71 B | USA |
 |
Repro Med Systems
KRMD
|
11.8 M | $ 5.37 | -1.56 % | $ 245 M | USA |
 |
Haemonetics Corporation
HAE
|
612 M | $ 65.87 | -0.15 % | $ 3.32 B | USA |
 |
electroCore
ECOR
|
2.8 M | $ 6.83 | -3.73 % | $ 37.7 K | USA |
 |
AngioDynamics
ANGO
|
135 M | $ 10.2 | 2.2 % | $ 417 M | USA |
 |
ICU Medical
ICUI
|
1.56 B | $ 149.04 | -0.66 % | $ 3.63 B | USA |
 |
InfuSystem Holdings
INFU
|
47.3 M | $ 8.14 | 1.12 % | $ 168 M | USA |
 |
The Cooper Companies
COO
|
1.41 B | $ 80.95 | 0.72 % | $ 16.1 B | USA |
 |
Masimo Corporation
MASI
|
1.09 B | $ 134.5 | -1.29 % | $ 7.17 B | USA |
 |
Harvard Bioscience
HBIO
|
46.2 M | $ 0.5 | -7.06 % | $ 21.2 M | USA |
 |
Glaukos Corporation
GKOS
|
75.6 M | $ 117.26 | -1.43 % | $ 5.68 B | USA |
 |
Merit Medical Systems
MMSI
|
713 M | $ 80.09 | -0.19 % | $ 4.66 B | USA |
 |
OraSure Technologies
OSUR
|
106 M | $ 2.78 | -0.54 % | $ 207 M | USA |
 |
Isoray
ISR
|
3.13 M | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
184 M | $ 150.09 | 0.74 % | $ 4.68 B | USA |
 |
LeMaitre Vascular
LMAT
|
69 M | $ 84.08 | 0.26 % | $ 1.89 B | USA |
 |
Intuitive Surgical
ISRG
|
2.72 B | $ 505.88 | -0.33 % | $ 180 B | USA |
 |
STERIS plc
STE
|
3.06 B | $ 261.25 | -0.23 % | $ 25.8 B | USA |
 |
NeuroMetrix
NURO
|
1.35 M | - | 5.05 % | $ 9.02 M | USA |
 |
Microbot Medical
MBOT
|
1.91 M | $ 1.84 | -1.34 % | $ 18.8 M |  Israel |
 |
Nephros
NEPH
|
5.83 M | $ 4.4 | 0.23 % | $ 45.7 M | USA |
 |
Utah Medical Products
UTMD
|
20.2 M | $ 60.16 | -2.42 % | $ 218 M | USA |
 |
Milestone Scientific
MLSS
|
2.2 M | $ 0.29 | -0.7 % | $ 23.1 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.14 B | $ 23.07 | -1.28 % | $ 3.97 B | USA |
 |
Pro-Dex
PDEX
|
47.1 M | $ 38.84 | -1.43 % | $ 128 M | USA |
 |
Predictive Oncology
POAI
|
826 K | - | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
11.9 M | $ 13.69 | 0.48 % | $ 658 M | USA |
 |
Becton, Dickinson and Company
BDX
|
11.9 B | $ 201.67 | 0.29 % | $ 58 B | USA |
 |
Repligen Corporation
RGEN
|
354 M | $ 151.86 | -2.88 % | $ 8.46 M | USA |
 |
BioLife Solutions
BLFS
|
8.76 M | $ 22.08 | -2.21 % | $ 1.02 B | USA |
 |
Stereotaxis
STXS
|
11.9 M | $ 2.26 | -3.21 % | $ 182 M | USA |
 |
Retractable Technologies
RVP
|
34.1 M | $ 0.69 | 0.16 % | $ 20.7 M | USA |
 |
STAAR Surgical Company
STAA
|
74.3 M | $ 18.79 | -0.8 % | $ 923 M | USA |
 |
Teleflex Incorporated
TFX
|
1.34 B | $ 105.0 | -0.43 % | $ 4.92 B | USA |
 |
West Pharmaceutical Services
WST
|
1.89 B | $ 226.43 | -2.61 % | $ 16.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 12.28 | 0.04 % | $ 2.5 B | USA |